The work of a consultant antimicrobial pharmacist involves not only knowing about antimicrobial medicines but also understanding how people and organisations behave and collaborating with others to optimise… read more.
Implementation of penicillin allergy de-labelling calls for an understanding of the key barriers and enablers in healthcare systems – topics that the iNAAN and ALABAMA studies address, explains… read more.
The PALACE study showed that in people at low-risk of penicillin allergy, a direct oral challenge with penicillin was no less effective than standard allergy testing for determining… read more.
Neil Powell combines the roles of a consultant antimicrobial pharmacist and a clinical researcher at the Royal Cornwall Hospital in Truro. His current research is focused on the… read more.
Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently… read more.
The pilot study of pharmacist-led vitamin D point-of-care testing showed that the procedure was feasible in routine practice and, surprisingly, that more than half of participants had insufficient… read more.
Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
